Immix Biopharma, Inc. IMMX Accrued Research And Development Expenses
Accrued Research And Development Expenses at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept IMMX:AccruedResearchAndDevelopmentExpenses.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s accrued research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s accrued research and development expenses?
- Immix Biopharma, Inc. (IMMX) reported accrued research and development expenses of $4.4M in Q1 2026.
- How has Immix Biopharma, Inc.'s accrued research and development expenses changed year-over-year?
- Immix Biopharma, Inc.'s accrued research and development expenses increased by 73.5% year-over-year, from $2.54M to $4.4M.
- What is the long-term trend for Immix Biopharma, Inc.'s accrued research and development expenses?
- Over 3 years (2022 to 2025), Immix Biopharma, Inc.'s accrued research and development expenses has grown at a 283.9% compound annual growth rate (CAGR), from $57.5K to $3.25M.
- What does accrued research and development expenses mean?
- This represents the liability for research and development services that have been performed but not yet invoiced or paid by the company. It reflects the ongoing financial commitment to clinical trials and drug development activities that have been incurred but remain outstanding at the balance sheet date.